

Supplementary Table 1

Number of patients (n)	Total				NA	Crohn's disease				NA	Ulcerative colitis				NA	IBD unclassified	
	Mean	SD	Min	Max		Mean	SD	Min	Max		Mean	SD	Min	Max		IBDu 1	IBDu 2
Age (Years)	42.3	17.3	18.0	85.0		37.6	15.3	18.0	71.0		51.2	17.5	27.0	85.0		65.0	25.0
Age at diagnosis (Years)	26.0	14.9	9.0	78.0		19.4	8.2	9.0	38.0		37.3	15.4	19.0	78.0		61.0	11.0
Gender (Female/Male) (%)	51.2	48.8				46.2	53.8				61.5	38.5				50.0	50.0
Montreal UC (E1/E2/E3) (%)											0	31	69			0	100
Montreal CD (A1/A2/A3) (%)						46	54	0									0
Montreal CD (L1/L2/L3/L4) (%)						8	27	65	19								
Montreal CD (B1/B2/B3/p) (%)						38	38	27	42								
Medication at time of study																	
Adalimumab (%)	17					19					8					0	
Infliximab (%)	17					23					8					0	
Azathioprine/6-MP (%)	34					35					31					50	
Methotrexate (%)	7					4					15					0	
Remission (%)	73					77					62					100	
CRP (mg/L) (0.0-5.0)	2.6	2.9	0.1	13.2	n=3	3.0	2.5	0.1	10.6	n=2	2.1	3.7	0.1	13.2	n=1	IBDu 1	IBDu 2
HGB (Female) (g/L) (120-150)	158	17	136	196		160	17	141	196		157	20	136	184		154.00	152.00
HGB (Male) (g/L) (130-170)	155	19	109	196		153	22	109	196		156	13	140	174			
RBC (Female) (10 ¹² /L) (3.8-5.8)	4.8	0.6	3.7	6.0		4.9	0.5	4.1	5.9		4.8	0.8	3.9	6.0		4.6	
RBC (Male) (10 ¹² /L) (4.5-6.5)	4.7	0.6	3.1	5.9		4.7	0.7	3.1	5.9		4.6	0.6	3.7	5.3			4.4
HCT (Female) (L/L) (0.36-0.46)	0.46	0.06	0.39	0.57		0.46	0.05	0.40	0.56		0.47	0.06	0.39	0.57		0.44	
HCT (Male) (L/L) (0.40-0.50)	0.45	0.06	0.34	0.59		0.45	0.07	0.34	0.59		0.45	0.04	0.40	0.50			0.42
MCV (fl) (83 - 101)	96	6	81	110		95	6	81	110		98	5	93	107		97	98
WBC (10 ⁹ /L) (4.0-11.0)	6.6	2.1	3.1	12.8		6.6	2.2	3.1	12.8		6.5	1.9	3.8	10.0		5.6	7.4
NEU (10 ⁹ /L) (2.0 -7.0)	4.2	1.6	2.0	8.7		4.3	1.7	2.0	8.7		4.2	1.4	2.3	6.8		2.8	4.8
LYM (10 ⁹ /L) (1.0 -4.0)	1.6	0.7	0.5	3.8		1.5	0.6	0.5	2.8		1.8	0.8	0.8	3.8		1.9	1.9
MON (10 ⁹ /L) (0.2 - 1.0)	0.5	0.3	0.1	1.3		0.6	0.3	0.1	1.3		0.5	0.2	0.2	0.8		0.7	0.5
EOS (10 ⁹ /L) (0.02-0.5)	0.2	0.2	0.0	1.2		0.2	0.2	0.0	1.2		0.2	0.1	0.1	0.3		0.1	0.1
BAS (10 ⁹ /L) (0.02-0.1)	0.1	0.1	0.0	0.7		0.1	0.0	0.0	0.2		0.1	0.2	0.0	0.7		0.0	0.1
PLT (10 ⁹ /L) (150-400)	219	79	77	450		215	87	77	450		226	67	91	376		159	270

*Montreal CD:

The sum of percentages of L and B classification can exceed 100 percent since disease classes and modifier were counted individually.

*CRP:

For a total number of 3 patients with IBD no CRP measurements were obtained in a 2 weeks time window in respect to the date of blood sampling.